{"id":1902,"date":"2018-03-13T13:58:16","date_gmt":"2018-03-13T13:58:16","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=1902"},"modified":"2018-03-13T13:58:16","modified_gmt":"2018-03-13T13:58:16","slug":"approbation-aux-etats-unis-du-brevet-dutilisation-des-agonistes-fxr-contre-la-replication-de-hbv","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/approbation-aux-etats-unis-du-brevet-dutilisation-des-agonistes-fxr-contre-la-replication-de-hbv\/","title":{"rendered":"Approbation aux Etats-Unis du brevet d&#8217;utilisation des agonistes FXR contre la r\u00e9plication de HBV"},"content":{"rendered":"<p>ENYO Pharma a obtenu l\u2019approbation aux Etats-Unis du brevet d&#8217;utilisation des agonistes de FXR contre le virus de l&#8217;H\u00e9patite B (HBV). Ce brevet a fait l\u2019objet d\u2019un accord de licence exclusive avec l\u2019Inserm. Les agonistes FXR modifient la composition du complexe transcriptionnel du cccDNA de HBV provoquant une r\u00e9pression de l\u2019expression du cccDNA.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ENYO Pharma a obtenu l\u2019approbation aux Etats-Unis du brevet d&#8217;utilisation des agonistes de FXR contre le virus de l&#8217;H\u00e9patite B (HBV). Ce brevet a fait l\u2019objet d\u2019un accord de licence exclusive avec l\u2019Inserm. Les agonistes FXR modifient la composition du complexe transcriptionnel du cccDNA de HBV provoquant une r\u00e9pression de l\u2019expression du cccDNA.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/approbation-aux-etats-unis-du-brevet-dutilisation-des-agonistes-fxr-contre-la-replication-de-hbv\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-1902","post","type-post","status-publish","format-standard","hentry","category-latest-news-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/latest-news-fr\/\" rel=\"category tag\">Br\u00e8ves<\/a>","rttpg_excerpt":"ENYO Pharma a obtenu l\u2019approbation aux Etats-Unis du brevet d&#8217;utilisation des agonistes de FXR contre le virus de l&#8217;H\u00e9patite B (HBV). Ce brevet a fait l\u2019objet d\u2019un accord de licence exclusive avec l\u2019Inserm. Les agonistes FXR modifient la composition du complexe transcriptionnel du cccDNA de HBV provoquant une r\u00e9pression de l\u2019expression du cccDNA.Lire la suite&nbsp;&raquo;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=1902"}],"version-history":[{"count":8,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1902\/revisions"}],"predecessor-version":[{"id":1913,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1902\/revisions\/1913"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=1902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=1902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=1902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}